Washington, October 29: A novel influenza vaccine, which is delivered nasally, has been found to trigger robust immunity in ferrets, say researchers.
Experts at NanoBio Corporation have revealed that the immune responses elicited by the new vaccine were more than 20 times higher than those generated by two injections of the currently approved vaccines.
The researchers also revealed that their intranasal vaccine used only half the standard antigen dose to produce that effect.
According to them, their nasal vaccines exert adjuvant activity without the need for pro-inflammatory materials, toxins or cytokines.